Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tert-Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.47 |
| ▸ | PPARG | P37231 | 12/20 | 0.47 |
| ▸ | PPARD | Q03181 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962831 | 0.98 | PPARA (0.49) | PPARAPPARGPPARDFFAR1LTB4R2 | |
| SCHEMBL3960456 | 0.90 | FFAR1 (0.43) | PPARAPPARGPPARDFFAR1LTB4R2 | |
| Tert-Butylamine SCHEMBL3962778 | 0.90 | PPARA (0.49) | PPARAPPARGPPARDLTB4R2TRPM8 | |
| SCHEMBL3968805 | 0.88 | PPARA (0.48) | PPARAPPARGPPARDHTR2AUSP2 | |
| SCHEMBL3959985 | 0.86 | PPARA (0.52) | PPARAPPARGPPARDLTB4R2TRPM8 | |
| SCHEMBL4898468 | 0.86 | PPARA (0.52) | PPARAPPARGPPARDLTB4R2TRPM8 | |
| SCHEMBL3963764 | 0.84 | PPARA (0.47) | PPARAPPARGPPARDHTR2A | |
| SCHEMBL4073462 | 0.84 | PPARA (0.47) | PPARAPPARGPPARDHTR2A | |
| SCHEMBL3962800 | 0.84 | PPARA (0.47) | PPARAPPARGPPARDHTR2A | |
| SCHEMBL3965062 | 0.84 | PPARA (0.47) | PPARAPPARGPPARDHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-7462644-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| EP-1572626-A1 | THERAPEUTIC AGENTS | Astrazeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004056748-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | PPARA 539/4885PPARG 479/4885PPARD 698/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARA 346/4885PPARG 228/4885PPARD 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.